Three-Strain Probiotic Formulations for Gut Microbiota Imbalance

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Chronic diseases such as metabolic syndrome, depression, osteoporosis, and neurodegeneration are exacerbated by imbalances in the gut microbiota, which are not effectively addressed by current probiotic and prebiotic treatments.

Innovation Solution

Probiotic formulations comprising Lactobacillus fermentum NCIMB S221, Lactobacillus plantarum NCIMB 8826, and Bifidobacteria longum spp. infantis NCIMB 702255, optionally combined with triphala or herbal rasayana formula, are administered to restore gut microbiota balance and modulate immune and neurological health.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional probiotic and prebiotic treatments are used, then gut microbiota balance is partially restored, but chronic diseases such as metabolic syndrome, depression, osteoporosis, and neurodegeneration are not effectively addressed

Engineering Contradiction:

Improveeffectiveness in treating chronic diseasesVSAvoidscope of disease treatment

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent combines three specific probiotic strains (Lactobacillus fermentum NCIMB S221, Lactobacillus plantarum NCIMB 8826, and Bifidobacteria longum spp. infantis NCIMB 702255) into a multi-strain formulation that synergistically addresses multiple chronic diseases simultaneously, expanding the scope of treatment beyond single-strain probiotics

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The probiotic formulation is designed to treat multiple chronic conditions including metabolic syndrome, depression, osteoporosis, and neurodegeneration, making it a universal treatment approach that addresses diverse disease mechanisms through a single multi-functional formulation

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Reliability

If gut microbiota imbalance is present, then digestive health and immune function are compromised, but current treatments do not sufficiently restore balance and prevent chronic diseases

Engineering Contradiction:

Improverestoration of gut microbiota balanceVSAvoidstrength of therapeutic effect

Core Design Contradiction:

ReliabilityVSPower

Solution Approach 1:

The patent selects specific probiotic strains with distinct functional characteristics tailored to address particular aspects of gut microbiota imbalance and chronic disease prevention, with each strain contributing specialized benefits to the overall formulation

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The formulation combines multiple probiotic strains in specific proportions to create a composite microbial community that produces synergistic effects, enhancing the overall therapeutic power and restoration of gut microbiota balance beyond individual strains

Inventive Principle:

Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The formulations effectively reduce markers of diabetes, obesity, inflammation, oxidative stress, and neurodegeneration, enhancing longevity and managing insulin resistance.

Implementation Method 1

Modulation of the microbiota with beneficial bacterial species (probiotics) and flora-promoting indigestible carbohydrates (prebiotics) reverses dysbiosis and promotes an anti-inflammatory and anti-oxidative environment

Methodology Applied

Scientific EffectProbiotic modulation of gut microbiota:

Data Source

PatentUS12419919B2Probiotic formulations for the treatment and alleviation of metabolic and oxidative stress, inflammation and neurodegeneration

Publication Date: 2025.09.23 PROVIVA PHARMA INC

AI summary

Provided herein is a product comprising three bacterial strains that are Lactobacillus fermentum NCIMB 5221, Lactobacillus plantarum NCIMB 8826 and Bifidobacteria longum spp. infantis NCIMB 7022SS.